Could an HIV drug soothe stubborn throat reflux?
NCT ID NCT04383262
First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 3 times
Summary
This study tests whether fosamprenavir, an FDA-approved HIV medication, can help people with laryngopharyngeal reflux (LPR) who haven't gotten better with standard acid reducers. LPR causes chronic cough, hoarseness, and throat clearing, and current treatments often fall short. Researchers will give 104 participants either the drug or a placebo for 12 weeks to see if symptoms improve.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fosamprenavir (an HIV drug)
- What this could lead to
- If it works, this could provide a new treatment option for people with laryngopharyngeal reflux who haven't improved with standard acid-reducing medications.
- What could go wrong
- This is an early phase 2 trial with only 104 participants. The drug may not prove more effective than placebo, and side effects from the HIV medication could occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARYNGOPHARYNGEAL REFLUX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert Hospital
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.